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ABSTRACT
Background Excessive use of empirical antibiotics is
common in critically ill patients. Rapid biomarker-based
exclusion of infection may improve antibiotic stewardship
in ventilator-acquired pneumonia (VAP). However,
successful validation of the usefulness of potential
markers in this setting is exceptionally rare.
Objectives We sought to validate the capacity for
speciﬁc host inﬂammatory mediators to exclude
pneumonia in patients with suspected VAP.
Methods A prospective, multicentre, validation study of
patients with suspected VAP was conducted in 12
intensive care units. VAP was conﬁrmed following
bronchoscopy by culture of a potential pathogen in
bronchoalveolar lavage ﬂuid (BALF) at >104 colony
forming units per millilitre (cfu/mL). Interleukin-1 beta
(IL-1β), IL-8, matrix metalloproteinase-8 (MMP-8), MMP-
9 and human neutrophil elastase (HNE) were quantiﬁed
in BALF. Diagnostic utility was determined for
biomarkers individually and in combination.
Results Paired BALF culture and biomarker results were
available for 150 patients. 53 patients (35%) had VAP
and 97 (65%) patients formed the non-VAP group. All
biomarkers were signiﬁcantly higher in the VAP group
(p<0.001). The area under the receiver operator
characteristic curve for IL-1β was 0.81; IL-8, 0.74; MMP-
8, 0.76; MMP-9, 0.79 and HNE, 0.78. A combination of
IL-1β and IL-8, at the optimal cut-point, excluded VAP
with a sensitivity of 100%, a speciﬁcity of 44.3% and a
post-test probability of 0% (95% CI 0% to 9.2%).
Conclusions Low BALF IL-1β in combination with IL-8
conﬁdently excludes VAP and could form a rapid
biomarker-based rule-out test, with the potential to
improve antibiotic stewardship.
INTRODUCTION
Antibiotic resistance has been increasing rapidly,
making antibiotic stewardship a priority for health-
care systems globally. Patients admitted to the inten-
sive care unit (ICU) receive a signiﬁcant burden of
antibiotics.1 Ventilator-acquired pneumonia (VAP)
occurs in 10%–20% of the ICU population.2 VAP
poses a dilemma for clinicians seeking to improve
antibiotic stewardship. The diagnosis of VAP is
challenging and pulmonary infection is conﬁrmed
in only approximately 30% of patients with sus-
pected VAP.3 4 Despite this, since VAP is associated
with signiﬁcant mortality and morbidity, and
because signiﬁcant delays in appropriate treatment
have been linked to increases in mortality,5 patients
are often treated with antibiotics from the moment
of initial suspicion. This is compounded by the fact
that conventional microbiology culture and sensi-
tivity results typically take up to 72 h to return to
clinicians.
Novel biomarker-based diagnostic techniques, if
suitably accurate and rapid, would offer a signiﬁ-
cant change in the clinical information available at
the time of suspected infection and could reduce
Key messages
What is the key question?
▸ Ventilator-acquired pneumonia (VAP) is
notoriously difﬁcult to diagnose clinically, so
this multicentre study aimed to determine
whether VAP could be rapidly and accurately
excluded by quantifying host biomarkers.
What is the bottom line?
▸ Low concentrations of interleukin-1 beta and
interleukin-8 effectively exclude VAP using a
system that yields results within 6 h.
Why read on?
▸ To our knowledge, this is the ﬁrst study to
validate the effective, rapid exclusion of VAP
using host proteins, paving the way for future
trials assessing whether these markers can
improve antibiotic stewardship in the intensive
care unit.
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unnecessary antibiotic use. However, to our knowledge, no
protein biomarkers showing promise in initial derivation studies
have gone on to yield conﬁrmatory diagnostic utility in multi-
centre validation studies.
In a single-centre derivation cohort, mediators of the host
inﬂammatory response measured in bronchoalveolar lavage
(BAL) ﬂuid from patients with suspected VAP demonstrated
potential as biomarkers for the exclusion of pneumonia. In par-
ticular, low concentrations of BAL ﬂuid interleukin (IL)-1β
appeared to be able to rule out VAP effectively.6 IL-8 and the
neutrophil proteases matrix metalloproteinase-8 (MMP-8),
MMP-9 and human neutrophil elastase (HNE) also showed
promise in excluding VAP.7 We, therefore, conducted a prag-
matic multicentre validation study of these ﬁve BAL ﬂuid bio-
markers in patients with suspected VAP.
METHODS
Study design and participants
We conducted a prospective, multicentre, observational study in
12 general UK ICUs, with screening performed on week days
between February 2012 and February 2013. A wide case mix of
medical, surgical and trauma patients was represented. Patients
were eligible if they were aged 18 years or more and if they had
been endotracheally intubated and mechanically ventilated for at
least 48 h. VAP was suspected if the patient had new or worsen-
ing alveolar shadowing on chest radiograph (CXR) and if at
least 2 of the following criteria were present: purulent tracheal
secretions; temperature <35°C or >38°C; or a blood white cell
count <4×109/L or >11×109/L. Patients were excluded based
on criteria predicting poor tolerance of bronchoscopy and BAL:
PaO2 <8 kPa on FiO2 >0.7; positive end-expiratory pressure
>15 cm H2O; peak airway pressure >35 cm H2O; heart rate
>140 bpm; mean arterial pressure <65 mm Hg; bleeding diath-
esis (including platelet count <20×109/L or international nor-
malised ratio >3); or intracranial pressure >20 mm Hg. Patients
were also excluded if the ICU clinician responsible for the
patient’s care considered the procedure to be unsafe, if the
patient had a previous BAL as part of this study or if consent/
assent was not obtained.
Consent or assent was obtained according to approved proce-
dures for incapacitated adults. The study was approved by the
appropriate research ethics committees within the National
Research Ethics Service (England and Northern Ireland (11/NE/
0242), Scotland (11/SS/0089)). Study monitoring and oversight
were provided by Newcastle Clinical Trials Unit.
Procedures
Participants underwent a protocolised bronchoscopy and BAL
performed by either the clinical team or local investigators. In
summary, BAL was performed in a region of the lung corre-
sponding to an area of new alveolar inﬁltrate on CXR. If mul-
tiple areas were involved, the BAL was performed in a segment
or subsegment from which purulent secretions were visualised.
If the CXR changes were extensive or there was doubt over
which segment to lavage, the posterior segment of the right
lower lobe was sampled.8 Patients received 100% oxygen and
sedation with or without paralysis according to the clinical
team’s preference. The bronchoscope was gently wedged in the
segment to be lavaged. The ﬁrst 20 mL saline instillate was aspi-
rated and discarded. Thereafter, three 40 mL aliquots of saline
were instilled, aspirated and pooled.
A 2 mL aliquot of BAL ﬂuid was sent to a National Health
Service or Public Health England microbiology laboratory for
semiquantitative culture. BAL ﬂuid was handled according to a
standard operating procedure in accordance with the UK
Standards for Microbiological Investigation.9 VAP was con-
ﬁrmed by growth of potential pathogens at >104 colony
forming units per millilitre (cfu/mL), the value of which as a ref-
erence test in VAP has been discussed extensively elsewhere.2
Sterile specimens or growth below this threshold identiﬁed the
‘non-VAP’ group. The remaining BAL ﬂuid was centrifuged at
700 g for 10 min. The supernatant was aspirated and stored
frozen for subsequent biomarker quantiﬁcation, which was per-
formed at a single site (Newcastle University) at the end of
study recruitment. Therefore, routine clinical care was provided
to all patients involved, without access to biomarker results.
Biomarkers in BAL ﬂuid were measured by cytometric bead
array (CBA) and analysed using an Accuri C6 ﬂow cytometer
(Becton Dickinson Biosciences, New Jersey, USA). Results are
generated within approximately 4 h. Levels of IL-1β, IL-8,
MMP-8, MMP-9 and HNE were determined in BAL ﬂuid in a
5-bead multiplex according to the manufacturer’s instructions.
CBA kits for IL-1β and IL-8 were commercially available,
whereas CBA kits for MMP-8, MMP-9 and HNE were custom-
made for the study. All samples were measured in dilutions of
1:5, 1:50 and 1:500. Samples which fell below the standard
range in the 1:5 dilution were repeated using undiluted BAL
ﬂuid. CBA was carried out by a single trained investigator, who
was unaware of the culture results, in a separate laboratory to
which BAL ﬂuid cultures were performed.
Clinical data were collected on ICU length of stay, duration of
mechanical ventilation, time to ICU and hospital discharge,
in-hospital mortality, ICU mortality, admission category
(medical or surgical), Acute Physiology and Chronic Health
Evaluation II score on admission, use of renal replacement
therapy, use of vasopressors, use of corticosteroids and whether
criteria for acute respiratory distress syndrome were met.10 Data
were also collected on antibiotic use on day of enrolment and
during the preceding 72 h; and antibiotic days and antibiotic-
free days (AFD) in the 7 days following BAL.
Statistical considerations
Sample size was estimated from the derivation study post-test
probability (PTP) of VAP using the IL-1β threshold value for
exclusion.6 Below the threshold, IL-1β excluded VAP with a
PTP of 2.8% (95% CI 0.1% to 15.9%). To improve the external
validity of this result, a sample size was based on narrowing the
95% CI. We estimated that 24% of patients would have con-
ﬁrmed VAP based on the derivation cohort. A sample size of
140 was estimated to allow a 95% CI for a PTP of 3% to be 0%
to 8%, which was judged tight enough for potential clinical use.
We, therefore, planned to recruit 160 patients to allow for a
dropout rate of approximately 15%.
Statistical analysis was performed using SPSS V.19 (Chicago,
Illinois, USA) and R 3.0.0.11 Comparisons for non-normally dis-
tributed continuous data were made with the Mann–Whitney
U test, otherwise with the Student t test. Binary outcomes were
analysed using the χ2 test.
Since the objective was to validate a rule-out for VAP, the stat-
istical analysis was performed to determine the maximum sensi-
tivity and negative predictive value (NPV). Patients were
dichotomised into a VAP group and non-VAP group according
to growth in BAL ﬂuid of >104 cfu/mL or ≤104 cfu/mL.
Individual biomarkers that were signiﬁcantly different between
groups were analysed by receiver operator characteristic (ROC)
procedures. Biomarkers were log10 transformed with the add-
ition of a constant of one before being tested in combination.
Log10 transformed biomarkers were entered into a logistic
Critical care
42 Hellyer TP, et al. Thorax 2015;70:41–47. doi:10.1136/thoraxjnl-2014-205766
group.bmj.com on January 29, 2018 - Published by http://thorax.bmj.com/Downloaded from 
regression model and ROC curves were constructed from the
predictive model. Cut-points for individual biomarkers and
combinations were determined by ﬁxing a minimum NPV of
95%. The diagnostic rules, diagnostic performance measures
and associated 95% CIs were derived using the
OptimalCutpoints library in R3.0.0.12
RESULTS
Four hundred and ﬁfteen patients satisﬁed criteria for suspected
VAP, of whom 248 had exclusion criteria. Of the remaining 167
patients, 150 had paired microbiological culture and biomarker
results from BAL ﬂuid and were entered into the analysis.
Fifty-three patients (35%) had conﬁrmed VAP and the remaining
97 (65%) patients comprised the non-VAP group. The Standards
for Reporting of Diagnostic Accuracy (STARD) diagram is pro-
vided at the end of the Results section, after the rationale for
the optimal diagnostic test has been described.
The VAP and non-VAP groups were similar in terms of demo-
graphics and clinical characteristics (table 1). The VAP group
was associated with less use of antibiotics prior to BAL, less use
of corticosteroids and a higher proportion of surgical patients,
but only the ﬁrst of these was statistically signiﬁcant (table 1).
The organisms grown at >104 cfu/mL are shown in table 2.
Gram-negative bacteria accounted for approximately 60% of
identiﬁed organisms, Gram-positive organisms 30% and fungi
10%. In the VAP group, 39 patients (73%) had growth of a
single micro-organism, 12 (23%) had two micro-organisms and
2 patients had three micro-organisms cultured at >104 cfu/mL.
One hundred and ten patients (73.3%) were receiving anti-
biotics at the time of BAL, but only 35 patients (23.3%) had a
new antibiotic started in the 72 h before BAL, with no signiﬁcant difference between the VAP and non-VAP groups
(p=0.078). In the 7 days following BAL, 57.6% of patients had
no AFD, with the median AFD being 0 (IQR 0–2) days. The
distribution of AFD in the 7 days following BAL is shown in
ﬁgure 1.
There were signiﬁcant differences in the concentrations of
IL-1β, IL-8, MMP-8, MMP-9 and HNE in BAL ﬂuid when com-
paring the VAP and non-VAP groups (p<0.001 for all compari-
sons) (table 3). Therefore, ROC curves were constructed for all
5 biomarkers to determine diagnostic utility and optimum
cut-off points. Selecting cut-points to obtain a minimum NPVof
Table 1 Patient characteristics.
Characteristic
VAP
(N=53)
Non-VAP
(N=97) p Value
Age (years) 56.3±17.7 55.2±17.3 0.48
Male—n (%) 42 (79.2) 69 (71.1) 0.28
Time from ICU admission to consent
(days)—median (IQR)*
5 (4–8) 7 (4–11) 0.43
APACHE II score on admission 17.3±6.0 19.1±7.8 0.15
Surgical admission—n (%) 31 (58.5) 41 (42.3) 0.06
Medical admission—n (%) 22 (41.5) 56 (57.7) 0.06
Hospital mortality—n (%)† 19 (38.8) 31 (33) 0.49
Hospital LOS (days)—median (IQR)‡ 39 (25–65) 36 (20–51) 0.26
ICU LOS (days)—median (IQR)§ 17 (14–34) 17 (11–31) 0.21
Renal replacement therapy—n (%)¶ 5 (9.4) 12 (12.5) 0.57
Vasopressors—n (%)† 12 (23.1) 35 (36.5) 0.10
ARDS criteria—n (%)** 8 (16) 19 (21.3) 0.44
Receipt of corticosteroids—n (%)* 7 (13.2) 21 (22.8) 0.16
Antibiotics at time of BAL—n (%) 30 (56.6) 80 (82.5) 0.001
New antibiotics started in 72 hours
before BAL—n (%)
8 (15.1) 27 (27.8) 0.08
Antibiotic days in the 7 days post BAL
—median (IQR)*
7 (5–7) 6.5 (4–7) 0.43
Antibiotic-free days (AFD) in the
7 days following BAL—median (IQR)*
0 (0–2) 0 (0–2.3) 0.21
Plus/minus values are mean±SD.
Data missing for: *5 patients; †7 patients; ‡21 patients; §2 patients; ¶1 patient and
**11 patients.
APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute
respiratory distress syndrome; BAL, bronchoalveolar lavage; ICU, intensive care unit;
LOS, length of stay; VAP, ventilator-acquired pneumonia.
Table 2 Organisms cultured at >104 cfu/mL
Organism N
Methicillin-sensitive Staphylococcus aureus 14
Escherichia coli 8
Pseudomonas aeruginosa 7
Klebsiella pneumoniae 5
Haemophilus spp 6
Candida spp 5
Enterobacter aerogenes 2
Enterobacter cloacae 1
Acinetobacter spp 2
Coliform 2
Moraxella catarrhalis 2
Upper respiratory flora* 2
Streptococcus pneumoniae 2
Proteus mirabilis 2
Serratia marcescens 1
Citrobacter koseri 1
Stenotrophomonas maltophilia 1
Streptococcus pyogenes 1
Methicillin-resistant Staphylococcus aureus 1
Peptostreptococcus spp 1
Yeasts 2
Streptococcus group C 1
N, the number of patients in whom the micro-organism in question was isolated from
bronchoalveolar lavage fluid at >104 cfu/mL.
*In both cases, normal flora growth was in addition to another organism at >104 cfu/mL.
Figure 1 Frequency distribution of AFD in the 7 days following
bronchoalveolar lavage. AFD, antibiotic-free days, represented as an
integer value.
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95% resulted in unacceptably low speciﬁcity for IL-8, MMP-8
and HNE (table 4).
Log10 transformed biomarkers were highly correlated, with
Pearson’s correlation coefﬁcients ranging from 0.79 to 0.93.
IL-1β was the strongest individual predictor of VAP; therefore,
combinations of biomarkers were tested with IL-1β. ROC
curves were constructed for combinations and performance at
optimal cut-points derived. The top performing biomarker com-
binations were IL-1β/IL-8/MMP-8/MMP-9 (cut-point −1.7015
on the scale of the linear predictor) with a sensitivity of 100%
and a speciﬁcity of 46.4%, and IL-1β/IL-8 (cut-point −1.7616
on the scale of the linear predictor) with a sensitivity of 100%
and a speciﬁcity of 44.3% (table 4).
The area under the ROC curve (AUROC) for the IL-1β/IL-8
combination was 0.81 (95% CI 0.74 to 0.88) (ﬁgure 2). Our aim
of achieving a high NPV resulted in a lower speciﬁcity; however,
either of these biomarker combinations could exclude VAP with a
PTP of 0% (95% CI 0% to 7.8% for the 4-biomarker combin-
ation; 0% to 9.2% for the 2-biomarker combination).
A 2-biomarker combination would have pragmatic advantages
over a 4-biomarker combination for future clinical application.
As a further validation of the logistic regression model, the 2-
biomarker model was applied to the biomarkers from the deriv-
ation cohort.6 7 The resulting AUROC was 0.85 (95% CI 0.75 to
0.94). Using the same cut-point of −1.7616 yielded a sensitivity
of 94.1%, a speciﬁcity of 56.4% and an NPVof 96.9%.
The STARD diagram for the study is shown in ﬁgure 3.
DISCUSSION
This multicentre validation cohort from a broad ICU population
yielded results very similar to those from our previous single-
centre derivation cohort. The optimal cut-offs for IL-1β were
also similar in the 2 studies (10 vs 17 pg/mL), the small difference
probably being explained by the lower volume of BAL instilled in
this study (120 mL vs 200 mL). The data, therefore, potentially
provide important information towards the development of new,
rapid diagnostic strategies for infection in the ICU. Successful
validation of initially promising derivation studies has repre-
sented a major hurdle in the development of new diagnostics in
the ICU setting. Of the ﬁve biomarkers investigated, all were sig-
niﬁcantly higher in VAP than in the non-VAP group. We demon-
strate that IL-1β, in particular, is a powerful biomarker for the
exclusion of VAP. Indeed, when the diagnostic utility of combina-
tions of biomarkers was tested, IL-1β was the predominant com-
ponent of all models. The combination of IL-1β and IL-8 could
exclude VAP with an NPV of 1, suggesting this simple combin-
ation has signiﬁcant potential as a rule-out test for VAP. The cut-
point was selected with the aim of determining the optimal
characteristics for exclusion of VAP. With an NPVof 1 but a posi-
tive predictive value of 0.50, the biomarkers reﬂect the perform-
ance of a satisfactory ‘rule-out’ test. Furthermore, this assay
typically takes approximately 4 h to perform, yielding a rapid
and novel biomarker combination to exclude VAP.
There is growing evidence that short courses of antibiotics for
suspected sepsis in the ICU may be safe. In contrast, there is evi-
dence that overuse of antibiotics could be harmful.13 Our data
suggest that if empirical antibiotics were started in all patients with
suspected VAP, they could potentially be discontinued with high
conﬁdence within a few hours in response to low IL-1β and IL-8
concentrations in BAL ﬂuid. If clinicians were prepared to change
antibiotic prescription based on the rule-out results, we estimate
that up to 30% of patients with suspected VAP could have early
Table 3 Biomarker concentration
Biomarker VAP Non-VAP p Value AUROC (95% CI)
IL-1β pg/mL 712 (112–1999) 29 (3–184) <0.001 0.81 (0.74 to 0.88)
IL-8 pg/mL 7546 (1987–23 050) 1401 (369–4422) <0.001 0.74 (0.65 to 0.82)
MMP-8 ng/mL 734 (113–2792) 66 (11–325) <0.001 0.76 (0.68 to 0.84)
MMP-9 ng/mL 6840 (1721–22 221) 491 (106–3146) <0.001 0.79 (0.71 to 0.86)
HNE ng/mL 3882 (710–11 183) 349 (96–1473) <0.001 0.78 (0.70 to 0.85)
BAL fluid biomarker concentrations for VAP and non-VAP groups. Data are expressed as median and IQR.
AUROC, area under the receiver operator characteristic curve; BAL, bronchoalveolar lavage; HNE, human neutrophil elastase; IL, interleukin; MMP, matrix metalloproteinase; VAP,
ventilator-acquired pneumonia.
Table 4 Individual biomarkers and biomarker combinations
Biomarker/combination
Cut-point Sensitivity (95% CI)
Specificity
(95% CI) PPV (95% CI) NPV (95% CI) +LR (95% CI) −LR (95% CI)
PTP (%)
(95% CI)
IL-1β 17 pg/mL 96.2% (87.2 to 99.0) 43.3% (33.9 to 53.2) 0.48 (0.39 to 0.58) 0.96 (0.85 to 0.99) 1.70 (1.41 to 2.04) 0.09 (0.02 to 0.35) 4.5 (1.3 to 5.1)
IL-8 382 pg/mL 98.1% (90.1 to 99.7) 24.7% (17.2 to 34.2) 0.42 (0.33 to 0.50) 0.96 (0.80 to 0.99) 1.30 (1.16 to 1.47) 0.08 (0.01 to 0.55) 4 (0.7 to 19.5)
MMP-8 160 ng/mL 100% (93.3 to 100.0) 5.2% (1.7 to 11.6) 0.37 (0.29 to 0.45) 1.0 (0.57 to 1.0) 1.05 (1.01 to 1.10) 0.0 (NE) 0.0 (0.0 to 0.43)
MMP-9 296 ng/mL 96.2% (87.0 to 99.5) 43.4% (33.3 to 53.7) 0.48 (0.38 to 0.58) 0.96 (0.85 to 0.97) 1.70 (1.41 to 2.04) 0.09 (0.02 to 0.35) 4.5 (3.9 to 15.3)
HNE 161 ng/mL 98.1% (89.9 to 99.9) 34.0% (24.7 to 44.3) 0.45 (0.36 to 0.54) 0.97 (0.85 to 0.98) 1.49 (1.28 to 1.72) 0.06 (0.01 to 0.39) 2.9 (1.9 to 15.0)
IL-1β/IL-8 100% (93.2 to 100.0) 44.3% (34.2 to 54.8) 0.50 (0.39 to 0.59) 1.0 (0.92 to 1.0) 1.80 (1.50 to 2.15) 0.0 (NE) 0.0 (0.0 to 9.2)
IL-1β/IL-8/ MMP-9 98.1% (89.9 to 100.0) 44.3% (34.2 to 54.8) 0.49 (0.39 to 0.60) 0.98 (0.88 to 0.98) 1.76 (1.47 to 2.11) 0.04 (0.01 to 0.30) 2.3 (1.5 to 11.9)
IL-1β/IL-8/MMP-8/MMP-9 100% (93.3 to 100.0) 46.4% (36.2 to 56.8) 0.51 (0.41 to 0.60) 1.0 (0.92 to 1.0) 1.87 (1.55 to 2.24) 0.0 (NE) 0.0 (0.0 to 7.8)
IL-1β/IL-8/MMP-8/MMP-
9/HNE
98.1% (90.0 to 100.0) 46.4% (36.2 to 56.8) 0.50 (0.40 to 0.60) 0.98 (0.89 to 0.99) 1.83 (1.52 to 2.21) 0.04 (0.01 to 0.29) 2.2 (1.4 to 11.5)
Biomarkers were log10 transformed with the addition of a constant of one before fitting into logistic regression for combinations of biomarkers. The linear predictor from each logistic
regression was used to construct an ROC curve. Performance of each combination represents performance at the specific cut-point on the ROC curve.
HNE, human neutrophil elastase; IL, interleukin; −LR, negative likelihood ratio; +LR, positive likelihood ratio; MMP, matrix metalloproteinase; NE, not estimated; NPV, negative
predictive value; PPV, positive predictive value; PTP, post-test probability; ROC, receiver operator characteristic.
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discontinuation of antibiotics, when they would otherwise be
continued.
To our knowledge, no other biomarkers have been shown to
be so robust for the exclusion of VAP. The most widely investi-
gated biomarkers in VAP are procalcitonin and type 1 soluble
triggering receptor expressed on myeloid cells (sTREM-1),
which have been analysed in both BAL ﬂuid and serum.14–16 In
addition, other biomarkers, including elastin ﬁbres, copeptin,
nitrated proteins, serum β-d-glucan, pancreatic stone protein,
midregional pro-atrial natriuretic peptide, pentraxin 3, Clara
cell protein, leucocyte RNA proﬁles, leptin, and gene expres-
sion, have been investigated.17–27 These biomarkers have gener-
ally shown inconsistent results, often with poor diagnostic or
prognostic utility. The biomarkers analysed in the present study
potentially have biological plausibility in that IL-1β and IL-8 are
pro-inﬂammatory cytokines, while MMP-8, MMP-9 and HNE
may be released from activated neutrophils during degranula-
tion, and one might expect these mediators to be elevated in
regions of lung in which there is active infection.
The diagnostic criteria and method of sampling used have
been variable in previous biomarker studies in suspected VAP.
Although debate continues over the merits of bronchoscopic
and non-bronchoscopic methods for respiratory sampling in
terms of clinical outcomes, the need for consistent alveolar sam-
pling is probably of greater importance when measuring biomar-
kers in suspected VAP. VAP is known to be a patchy process,8
Figure 2 Receiver operator characteristic (ROC) curve of interleukin
(IL)-1β and IL-8 combination. ROC curve of linear predictor of IL-1β and
IL-8 logistic regression. Area under the ROC curve=0.81 (95% CI 0.74
to 0.88).
Figure 3 STARD diagram for IL-1β/
IL-8 combination. BAL, bronchoalveolar
lavage; IL, interleukin; VAP,
ventilator-acquired pneumonia; STARD,
Standards for Reporting of Diagnostic
Accuracy.
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and ‘blind’ BAL methods may (at least theoretically) either
sample unaffected alveolar regions or, worse, proximal non-
alveolar airway. When seeking VAP, it seems logical to sample
the alveolar regions of radiologically affected lung. Although
one other study did not show any diagnostic utility from
IL-1β,16 this variance to our ﬁndings may be due to sampling by
mini-BAL. Our results can only be extrapolated from the proto-
colised BAL used in this study, and certainly our cut-off values
cannot be extrapolated to mini-BAL, for example. Although the
practical implications and cost of BAL may be perceived as
potential disincentives, BAL is a common procedure in the ICU
and the full cost implications can only be considered once the
impact on antibiotic prescribing has been determined in future
studies.
Our study has a number of potential limitations. As with
many ICU studies, exclusion criteria eliminated 60% of patients
who met inclusion criteria, potentially reducing the generalis-
ability. A caveat of our reliance on BAL sampling is that some
patients are too unstable to tolerate the procedure. We estimate
that 67 patients (16%) who met inclusion criteria were excluded
on safety grounds precluding bronchoscopy (data not shown).
A further potential limitation is that a large proportion of
patients (73.3%) were on antibiotics at the time of BAL, which
could potentially have resulted in false negative microbiology
and, perhaps, even falsely low biomarker levels. However, far
fewer patients had a new antibiotic started in the 72 h before
BAL (23.3%) with no signiﬁcant difference between the VAP
and non-VAP groups. Importantly, this was a pragmatic valid-
ation study, and excluding patients on antibiotics would have
further limited its generalisability. Performing a subanalysis of
IL-1β to exclude patients who received new antibiotics in 72 h
before BAL (therefore including 69 non-VAP and 46 VAP
patients) resulted in an AUROC of 0.78 (95% CI 0.70 to 0.87),
suggesting that the effect of antibiotics may not be of great
signiﬁcance.
An additional consideration is that our ‘standard’ for the diag-
nosis of VAP—potential pathogens at >104 cfu/mL in BAL ﬂuid
—is imperfect. If a patient is on an antibiotic at the time of BAL
and a pathogen sensitive to that antibiotic is cultured, but at
<104 cfu/mL, clinicians may ﬁnd it hard to be absolutely conﬁ-
dent that VAP is excluded. The obvious difﬁculty here is that the
true diagnostic ‘gold standard’ of simultaneous culture and
histological examination of infected and inﬂamed alveolar tissue
is impractical. In this setting, quantitative culture generally per-
forms at least as well as other suggested diagnostic modalities,
and better than clinical diagnosis without sampling.2 28 Taken
overall, we can only conclude that our study validates the per-
formance of IL-1β and IL-8 in the speciﬁc setting of the proto-
colised BAL and the deﬁnition of VAP used here.
Furthermore, determining the highest achievable sensitivity
comes at the cost of speciﬁcity. As the speciﬁcity decreases, the
proportion of non-VAP patients correctly ruled out by the bio-
marker combination reduces. However, this trade-off is neces-
sary to exclude VAP with the lowest possible PTP, to give the
clinician conﬁdence in the rule-out performance and therefore
allow early antibiotic discontinuation. We also recognise that a
blood marker(s) excluding VAP would be far more desirable
than BAL ﬂuid markers, given that some patients may not be
suitable for BAL and that there is potential interoperator tech-
nical variability in BAL. However, at present, no good blood
biomarkers exist in this context.
A further issue concerns the ongoing controversy as to
whether Candida spp in BAL ﬂuid at >104 cfu/mL are con-
taminants or potentially pathogenic. We included Candida on
the basis that, in critically ill patients, clinicians may ﬁnd it
hard to ignore potential pathogens at such high concentra-
tions from an affected region of lung. In any event, isolated
growth of Candida was rare in our hands. Finally, a diagnostic
test is only valuable if it beneﬁcially alters practice, and it
remains to be seen whether clinicians will be prepared to alter
antibiotic use based on a biomarker test—this requires to be
scrutinised formally in the setting of a randomised controlled
trial.
In summary, this study conﬁrms that IL-1β effectively excludes
VAP when validated in a multicentre study. Performance is
improved further by the addition of IL-8, and the combination
could form a relatively simple, rapid diagnostic assay to exclude
VAP. Biomarker analysis appears to have the potential to
improve antibiotic stewardship early in the course of suspected
VAP. Whether this concept can lead to effective improvements
in antibiotic stewardship remains to be seen and should be the
focus of randomised controlled trials.
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